DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

OBJECTIVE: In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Buse, John B., Drucker, Daniel J., Taylor, Kristin L., Kim, Terri, Walsh, Brandon, Hu, Hao, Wilhelm, Ken, Trautmann, Michael, Shen, Larry Z., Porter, Lisa E.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2010
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2875434/
https://ncbi.nlm.nih.gov/pubmed/20215461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-1914
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky